The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...
A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results